Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia

Ann Allergy Asthma Immunol. 2017 Jul;119(1):85-86. doi: 10.1016/j.anai.2017.04.022. Epub 2017 May 9.

Authors

Kris McGrath¹, Brady Stein², Lindsey Kalhagen², Lauren Leighton³

Affiliations

¹ Division of Allergy and Immunology, Department of Medicine, Northwestern University, Chicago, Illinois. Electronic address: kgm716@gmail.com.
² Division of Hematology/Oncology, Department of Medicine, Northwestern University, Chicago, Illinois.
³ Division of Allergy and Immunology, Department of Medicine, Northwestern University, Chicago, Illinois.

PMID: 28499700
DOI: 10.1016/j.anai.2017.04.022

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents / adverse effects*
Dasatinib / adverse effects*
Eosinophilia / chemically induced*
Female
Humans
Imatinib Mesylate / adverse effects*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Protein Kinase Inhibitors / adverse effects*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Imatinib Mesylate
Dasatinib